Pacific Shuanglin Bio-pharmacy Co., Ltd. (000403.SZ) has a MoatMap StockRank of 37/100 based on Quality (49/100), Value (43/100), and Momentum (32/100) factor scores. The current signal is HOLD. Pacific Shuanglin is a leading Chinese blood products manufacturer with high regulatory barriers and a strong local moat, but it lacks the global scale and pricing power of top-tier CDMOs.
Pacific Shuanglin Bio-pharmacy is a specialized Chinese biotechnology company focused on the research, development, and production of blood products, including albumin and immunoglobulin. Operating in a highly regulated industry with strict licensing barriers, the company maintains a secure network of plasma collection stations across China. Its growth is driven by rising domestic demand for plasma-derived therapies and expanding production capacity.
| Price | $1.71 |
| Market Cap | $1.8B |
| P/E (TTM) | 34.24 |
| P/E (Forward) | 11.85 |
| Price/Book | 1.48 |
| Return on Equity | 4.4% |
| Return on Invested Capital | 6.2% |
| Debt/Equity | 9.71 |
| Gross Margin | 39.5% |
| Operating Margin | 6.1% |
| Revenue Growth | -8.5% |
| Dividend Yield | 4.2% |
| Free Cash Flow | $-15M |
Pacific Shuanglin Bio-pharmacy Co., Ltd. operates in the Biotechnology industry, part of the Healthcare sector (China).